PCRX's free cash flow for Q3 2023 was $41.04M. For the 2023 fiscal year, PCRX's free cash flow was decreased by $34.36M and operating cash flow was $44.44M. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Operating Cash Flow	$ 149.10M	$ 145.27M	$ 126.71M	$ 77.03M	$ 70.52M	$ 48.87M
Investing Cash Flow	$ 80.36M	$ -225.19M	$ -21.78M	$ -277.61M	$ -128.49M	$ 20.58M
Financing Cash Flow	$ -239.76M	$ -401.53M	$ 380.69M	$ 222.30M	$ 3.67M	$ 8.95M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 133.00M	$ 104.14M	$ 585.58M	$ 99.96M	$ 78.23M	$ 132.53M
Income Tax Paid Supplemental Data	$ 5.25M	$ 7.40M	$ 3.22M	$ 2.42M	$ 863.00K	$ 128.00K
Interest Paid Supplemental Data	$ 34.61M	$ 33.30M	$ 7.00M	$ 7.21M	$ 8.20M	$ 8.21M
Issuance Of Capital Stock	-	-	-	-	-	-
Issuance Of Debt	$ 90.17M	$ -78.13M	$ 363.75M	$ 402.50M	$ 0.00	$ 0.00
Repayment Of Debt	$ -59.38M	$ -78.13M	-	$ -209.88M	$ -338.00K	$ 0.00
Free Cash Flow	$ 130.25M	$ 115.20M	$ 80.84M	$ 39.23M	$ 60.36M	$ 34.36M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Pacira Pharmaceuticals Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing